Manon Laporte
Overview
Explore the profile of Manon Laporte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Y, Weynand B, Zhang X, Laporte M, Jochmans D, Neyts J
Viruses
. 2025 Feb;
17(2).
PMID: 40006927
Human parainfluenza virus type 3 (HPIV-3) can cause severe respiratory diseases, particularly in young children, the elderly and immunocompromised. There are no approved antiviral drugs against this virus. We report...
2.
Jing L, Zhao F, Zheng L, Meng B, Gao S, Laporte M, et al.
Int J Mol Sci
. 2025 Jan;
26(2.
PMID: 39859382
With the aim of developing novel anti-SARS-CoV-2 drugs to address the ongoing evolution and emergence of drug-resistant strains, the reported SARS-CoV-2 M inhibitor was selected as a lead to find...
3.
Kiarie I, Hoffka G, Laporte M, Leyssen P, Neyts J, Tozser J, et al.
Viruses
. 2024 Oct;
16(10).
PMID: 39459940
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important...
4.
Lin Y, Khan M, Weynand B, Laporte M, Coenjaerts F, Babusis D, et al.
Nat Commun
. 2024 Sep;
15(1):7765.
PMID: 39237507
Human parainfluenza virus type 3 (HPIV-3) can cause severe respiratory tract infections. There are no convenient small-animal infection models. Here, we show viral replication in the upper and lower airways...
5.
Diego J, Singh G, Jangra S, Handrejk K, Laporte M, Chang L, et al.
PLoS Pathog
. 2024 Jan;
20(1):e1011805.
PMID: 38198521
Hybrid immunity (vaccination + natural infection) to SARS-CoV-2 provides superior protection to re-infection. We performed immune profiling studies during breakthrough infections in mRNA-vaccinated hamsters to evaluate hybrid immunity induction. The...
6.
Escalera A, Laporte M, Turner S, Karakus U, Gonzalez-Reiche A, van de Guchte A, et al.
Emerg Microbes Infect
. 2023 Dec;
13(1):2297553.
PMID: 38112266
SARS-CoV-2 Omicron subvariants are still emerging and spreading worldwide. These variants contain a high number of polymorphisms in the spike (S) glycoprotein that could potentially impact their pathogenicity and transmission....
7.
Diego J, Singh G, Jangra S, Handrejk K, Laporte M, Chang L, et al.
bioRxiv
. 2023 Jul;
PMID: 37425792
Hybrid immunity to SARS-CoV-2 provides superior protection to re-infection. We performed immune profiling studies during breakthrough infections in mRNA-vaccinated hamsters to evaluate hybrid immunity induction. mRNA vaccine, BNT162b2, was dosed...
8.
Jochmans D, Laporte M, Neyts J
Cell Host Microbe
. 2023 Jun;
31(6):856-860.
PMID: 37321170
Broad(er)-acting antiviral drugs, active against entire genera or families of viruses, should be developed and stockpiled in epidemic/pandemic peacetime. They can be used to counter outbreaks as soon as the...
9.
Chiu W, Schepers J, Francken T, Vangeel L, Abbasi K, Jochmans D, et al.
Antiviral Res
. 2022 Dec;
210:105506.
PMID: 36565756
Massive efforts on both vaccine development and antiviral research were launched to combat the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We contributed, amongst others, by the development of...
10.
Stevaert A, Van Berwaer R, Mestdagh C, Vandeput J, Vanstreels E, Raeymaekers V, et al.
mBio
. 2022 Aug;
13(4):e0137622.
PMID: 35913162
The continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) urges better understanding of the functional motifs in the spike (S) protein and their tolerance to...